A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 360
Summary
- Conditions
- Ovarian Neoplasms
- Platinum Sensitive Ovarian Cancer
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Only males
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT01847274
- Collaborators
- European Network of Gynaecological Oncological Trial Groups (ENGOT)
- Myriad Genetics, Inc.
- US Oncology Research
- Sarah Cannon
- Cooperative Ovarian Cancer Group (COGI)
- Facing Our Risk of Cancer Empowered
- Investigators
- Study Director: GSK Clinical Studies GlaxoSmithKline